GSTS Celebrate Success of Inaugural Scientific Symposium and Launch Innovation Academy
News Jul 11, 2013
This inaugural scientific symposium welcomed over 100 attendees, offering participants great networking opportunities and the chance to hear presentations from a group of GSTS experts.
Discussions were focused into four tracks – child health, keeping people healthy, infectious diseases, and next-generation diagnostics – and on-show was the innovative approach to laboratory medicine that can be found throughout the GSTS organisation.
As the UK's leading independent provider of pathology services, GSTS and King's College Pathology LLP provide pathology services that make a real difference to patient care. The Innovation Academy was organised to create an environment to support innovation, quality and the development of future scientific leaders. Dr Harrington said “Today is about the scientists being heard. We have broken the science into four broad themes to help make potentially higher level science more accessible to the decision makers and executive teams, as well as for our users. This enables us to articulate the value that scientists bring to patients, medics, and to the GSTS organisation.”
Drawing from twelve senior scientists across the GSTS and KingsPath partnership, the presentations covered current trends and topical developments in areas such as expanded newborn screening, vitamin B12 deficiency, HIV drug resistance and pre-implantation genetic diagnosis. Dr Harrington said “Underneath today’s themes is some real high end science and this has come across because, after all, a subject matter expert is always the best person to articulate the enthusiasm for that area”.
Dr Harrington added, “There is currently a direction towards consolidation of laboratory services and this is a challenge, so having an event such as this where the collaboration can come together really helps partners learn and understand each others’ expertise.
The next event in the series is planned for 6th December 2013.
To find out more about innovation at GSTS and KingsPath, please visit: www.gsts.com
New Ovarian Cancer TargetNews
Researchers have found a prescription drug, Calcitriol, approved by the Food and Drug Administration for the treatment of calcium deficiency and kidney diseases, may increase the likelihood of surviving ovarian cancer. This new study opens a potential avenue for treating ovarian cancer. Since Calcitriol is an FDA-approved drug, no additional research is needed before the drug can advance to human clinical trials for ovarian cancer.READ MORE
Novel Microplate 3D Bioprinting Platform for Engineering Muscle and Tendon TissuesNews
There is a strong need for medication that treats age-related degenerative muscle and tendon diseases. A critical bottleneck in the discovery and development of novel drugs for skeletal muscle is the lack of efficient and robust functional in vitro assays for compound screening. Researchers describe the development of a novel screening platform with automated production of 3D muscle- and tendon–like tissues using 3D bioprinting.READ MORE
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE